The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease

Makoto Fujimoto, Koichi Tsuneyama, Hideki Kinoshita, Hirozo Goto, Yasuo Takano, Carlo Selmi, Carl L Keen, M. Eric Gershwin, Yutaka Shimada

Research output: Chapter in Book/Report/Conference proceedingConference contribution

21 Citations (Scopus)

Abstract

The Kampo formula keishibukuryogan (KBG, Guizhifulingwan) is frequently used in traditional Japanese and Chinese medicine to treat several symptoms and manifests anti-inflammatory and scavenging effects. Nonalcoholic fatty liver disease (NAFLD) is a common manifestation of the metabolic syndrome and has the potential to evolve to liver cirrhosis through chronic inflammation and steatohepatisis (NASH). We have recently reported the KBG significant effectiveness on liver injury in a NASH animal model that prompted us to prescribe to KBG (TJ-25). We performed a retrospective study and reviewed the charts of outpatients who were prescribed KBG for 8-12 weeks due to non-liver-related symptoms (n = 11) over the past year to evaluate the clinical outcome. In six of these cases, biochemical and ultrasound signs of NAFLD were observed. KBG led to a significant reduction in liver injury tests and blood cholesterol but had no effects on body weight in all NAFLD cases. Further, liver tests and lipid profiles returned to baseline values when KBG treatment was stopped. On the basis of data on a small number of subjects, we suggest that the use of KBG is a safe complementary treatment in patients with NAFLD. While it is unlikely that Kampo formulas may substitute the current nutritional approaches to the metabolic syndrome, future studies should address the possibility of an additive effect, possibly through anti-inflammatory mechanisms.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages151-158
Number of pages8
Volume1190
DOIs
StatePublished - Mar 2010

Publication series

NameAnnals of the New York Academy of Sciences
Volume1190
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Liver
Kampo Medicine
Inflammation
Wounds and Injuries
Anti-Inflammatory Agents
Chinese Traditional Medicine
Hematologic Tests
Liver Cirrhosis
Outpatients
Animal Models
Retrospective Studies
Cholesterol
Body Weight
Lipids
keishibukuryogan
Non-alcoholic Fatty Liver Disease
Scavenging
Therapeutics
Medicine
Animals

Keywords

  • Liver steatosis
  • Metabolic syndrome
  • Steatohepatitis
  • Traditional Japanese medicine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Fujimoto, M., Tsuneyama, K., Kinoshita, H., Goto, H., Takano, Y., Selmi, C., ... Shimada, Y. (2010). The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. In Annals of the New York Academy of Sciences (Vol. 1190, pp. 151-158). (Annals of the New York Academy of Sciences; Vol. 1190). https://doi.org/10.1111/j.1749-6632.2009.05265.x

The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. / Fujimoto, Makoto; Tsuneyama, Koichi; Kinoshita, Hideki; Goto, Hirozo; Takano, Yasuo; Selmi, Carlo; Keen, Carl L; Gershwin, M. Eric; Shimada, Yutaka.

Annals of the New York Academy of Sciences. Vol. 1190 2010. p. 151-158 (Annals of the New York Academy of Sciences; Vol. 1190).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Fujimoto, M, Tsuneyama, K, Kinoshita, H, Goto, H, Takano, Y, Selmi, C, Keen, CL, Gershwin, ME & Shimada, Y 2010, The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. in Annals of the New York Academy of Sciences. vol. 1190, Annals of the New York Academy of Sciences, vol. 1190, pp. 151-158. https://doi.org/10.1111/j.1749-6632.2009.05265.x
Fujimoto M, Tsuneyama K, Kinoshita H, Goto H, Takano Y, Selmi C et al. The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. In Annals of the New York Academy of Sciences. Vol. 1190. 2010. p. 151-158. (Annals of the New York Academy of Sciences). https://doi.org/10.1111/j.1749-6632.2009.05265.x
Fujimoto, Makoto ; Tsuneyama, Koichi ; Kinoshita, Hideki ; Goto, Hirozo ; Takano, Yasuo ; Selmi, Carlo ; Keen, Carl L ; Gershwin, M. Eric ; Shimada, Yutaka. / The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. Annals of the New York Academy of Sciences. Vol. 1190 2010. pp. 151-158 (Annals of the New York Academy of Sciences).
@inproceedings{f4d175e5d7f4426fb5775333dcbc885a,
title = "The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease",
abstract = "The Kampo formula keishibukuryogan (KBG, Guizhifulingwan) is frequently used in traditional Japanese and Chinese medicine to treat several symptoms and manifests anti-inflammatory and scavenging effects. Nonalcoholic fatty liver disease (NAFLD) is a common manifestation of the metabolic syndrome and has the potential to evolve to liver cirrhosis through chronic inflammation and steatohepatisis (NASH). We have recently reported the KBG significant effectiveness on liver injury in a NASH animal model that prompted us to prescribe to KBG (TJ-25). We performed a retrospective study and reviewed the charts of outpatients who were prescribed KBG for 8-12 weeks due to non-liver-related symptoms (n = 11) over the past year to evaluate the clinical outcome. In six of these cases, biochemical and ultrasound signs of NAFLD were observed. KBG led to a significant reduction in liver injury tests and blood cholesterol but had no effects on body weight in all NAFLD cases. Further, liver tests and lipid profiles returned to baseline values when KBG treatment was stopped. On the basis of data on a small number of subjects, we suggest that the use of KBG is a safe complementary treatment in patients with NAFLD. While it is unlikely that Kampo formulas may substitute the current nutritional approaches to the metabolic syndrome, future studies should address the possibility of an additive effect, possibly through anti-inflammatory mechanisms.",
keywords = "Liver steatosis, Metabolic syndrome, Steatohepatitis, Traditional Japanese medicine",
author = "Makoto Fujimoto and Koichi Tsuneyama and Hideki Kinoshita and Hirozo Goto and Yasuo Takano and Carlo Selmi and Keen, {Carl L} and Gershwin, {M. Eric} and Yutaka Shimada",
year = "2010",
month = "3",
doi = "10.1111/j.1749-6632.2009.05265.x",
language = "English (US)",
isbn = "9781573317900",
volume = "1190",
series = "Annals of the New York Academy of Sciences",
pages = "151--158",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease

AU - Fujimoto, Makoto

AU - Tsuneyama, Koichi

AU - Kinoshita, Hideki

AU - Goto, Hirozo

AU - Takano, Yasuo

AU - Selmi, Carlo

AU - Keen, Carl L

AU - Gershwin, M. Eric

AU - Shimada, Yutaka

PY - 2010/3

Y1 - 2010/3

N2 - The Kampo formula keishibukuryogan (KBG, Guizhifulingwan) is frequently used in traditional Japanese and Chinese medicine to treat several symptoms and manifests anti-inflammatory and scavenging effects. Nonalcoholic fatty liver disease (NAFLD) is a common manifestation of the metabolic syndrome and has the potential to evolve to liver cirrhosis through chronic inflammation and steatohepatisis (NASH). We have recently reported the KBG significant effectiveness on liver injury in a NASH animal model that prompted us to prescribe to KBG (TJ-25). We performed a retrospective study and reviewed the charts of outpatients who were prescribed KBG for 8-12 weeks due to non-liver-related symptoms (n = 11) over the past year to evaluate the clinical outcome. In six of these cases, biochemical and ultrasound signs of NAFLD were observed. KBG led to a significant reduction in liver injury tests and blood cholesterol but had no effects on body weight in all NAFLD cases. Further, liver tests and lipid profiles returned to baseline values when KBG treatment was stopped. On the basis of data on a small number of subjects, we suggest that the use of KBG is a safe complementary treatment in patients with NAFLD. While it is unlikely that Kampo formulas may substitute the current nutritional approaches to the metabolic syndrome, future studies should address the possibility of an additive effect, possibly through anti-inflammatory mechanisms.

AB - The Kampo formula keishibukuryogan (KBG, Guizhifulingwan) is frequently used in traditional Japanese and Chinese medicine to treat several symptoms and manifests anti-inflammatory and scavenging effects. Nonalcoholic fatty liver disease (NAFLD) is a common manifestation of the metabolic syndrome and has the potential to evolve to liver cirrhosis through chronic inflammation and steatohepatisis (NASH). We have recently reported the KBG significant effectiveness on liver injury in a NASH animal model that prompted us to prescribe to KBG (TJ-25). We performed a retrospective study and reviewed the charts of outpatients who were prescribed KBG for 8-12 weeks due to non-liver-related symptoms (n = 11) over the past year to evaluate the clinical outcome. In six of these cases, biochemical and ultrasound signs of NAFLD were observed. KBG led to a significant reduction in liver injury tests and blood cholesterol but had no effects on body weight in all NAFLD cases. Further, liver tests and lipid profiles returned to baseline values when KBG treatment was stopped. On the basis of data on a small number of subjects, we suggest that the use of KBG is a safe complementary treatment in patients with NAFLD. While it is unlikely that Kampo formulas may substitute the current nutritional approaches to the metabolic syndrome, future studies should address the possibility of an additive effect, possibly through anti-inflammatory mechanisms.

KW - Liver steatosis

KW - Metabolic syndrome

KW - Steatohepatitis

KW - Traditional Japanese medicine

UR - http://www.scopus.com/inward/record.url?scp=77950257025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950257025&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.05265.x

DO - 10.1111/j.1749-6632.2009.05265.x

M3 - Conference contribution

C2 - 20388146

AN - SCOPUS:77950257025

SN - 9781573317900

VL - 1190

T3 - Annals of the New York Academy of Sciences

SP - 151

EP - 158

BT - Annals of the New York Academy of Sciences

ER -